A novel cytarabine crystalline lipid prodrug: Hexadecyloxypropyl cytarabine 3′,5′-cyclic monophosphate for proliferative vitreoretinopathy

Molecular Vision

Volumn 18, Issue , 2012, Pages 1907-1917

  Kim, Jae Suk ^a,c   Beadle, James R ^b   Freeman, William R ^a   Hostetler, Karl Y ^b   Hartmann, Kathrin ^a   Valiaeva, Nadejda ^b   Kozak, Igor ^a   Conner, Laura ^a   Trahan, Julissa ^b   Aldern, Kathy A ^b   Cheng, Lingyun ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c Inje University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE DERIVATIVE; HEXADECYLOXYPROPYL CYTARABINE 3',5' CYCLIC MONOPHOSPHATE; HEXADECYLOXYPROPYL CYTARABINE 5' MONOPHOSPHATE; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOMICROSCOPY; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG CYTOTOXICITY; DRUG STRUCTURE; ELECTRORETINOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRAOCULAR PRESSURE; NONHUMAN; OCULOPLETHYSMOGRAPHY; OPHTHALMOSCOPY; PRIORITY JOURNAL; RAT; VITREORETINOPATHY;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ARABINONUCLEOTIDES; CELL LINE; CELL SURVIVAL; CYTIDINE MONOPHOSPHATE; DELAYED-ACTION PREPARATIONS; DIFFUSION CHAMBERS, CULTURE; ELECTRORETINOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; KINETICS; OPHTHALMOSCOPY; PRODRUGS; RABBITS; RATS; RETINA; RETINAL PIGMENT EPITHELIUM; SOLUBILITY; VITREORETINOPATHY, PROLIFERATIVE; VITREOUS BODY;

EID: 84865820686     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology 1983; 90:121-5. [PMID: 6856248]
2. Charteris DG. Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment. Br J Ophthalmol 1995; 79:953-60. [PMID: 7488586]
3. Pastor JC. Proliferative vitreoretinopathy: an overview. Surv Ophthalmol 1998; 43:3-18. [PMID: 9716190]
4. Asaria RH, Kon CH, Bunce C, Charteris DG, Wong D, Khaw PT, Aylward GW. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: Results from a randomized, double-blind, controlled clinical trial. Ophthalmology 2001; 108:1179-83. [PMID: 11425671]
5. Charteris DG, Aylward GW, Wong D, Groenewald C, Asaria RH, Bunce C. A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. Ophthalmology 2004; 111:2240-5. [PMID: 15582080]
6. Wickham L, Bunce C, Wong D, McGurn D, Charteris DG. Randomized controlled trial of combined 5-Fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy. Ophthalmology 2007; 114:698-704. [PMID: 17398320]
7. Garcia RA, Sanchez JG, Arevalo JF. Combined 5-fluorouracil, low-molecular-weight heparin, and silicone oil in the management of complicated retinal detachment with proliferative vitreoretinopathy grade C. Ophthalmic Surg Lasers Imaging 2007; 38:276-82. [PMID: 17674917]
8. Cheng L, Hostetler KY, Gardner MF, Avila CP Jr, Bergeron-Lynn G, Keefe KS, Wiley CA, Freeman WR. Intravitreal toxicology in rabbits of two preparations of 1-O-octadecylsn-glycerol-3-phosphonoformate, a sustained-delivery anti-CMV drug. Invest Ophthalmol Vis Sci 1999; 40:1487-95. [PMID: 10359331]
9. Peyman GA, Schulman J. Proliferative vitreoretinopathy and chemotherapeutic agents. Surv Ophthalmol 1985; 29:434-42. [PMID: 3892742]
10. Ruiz JC, Beadle JR, Aldern KA, Keith KA, Hartline CB, Kern ER, Hostetler KY. Synthesis and antiviral evaluation of alkoxyalkyl-phosphate conjugates of cidofovir and adefovir. Antiviral Res 2007; 75:87-90. [PMID: 17367874]
11. Markiewicz WT, Panyukova NS, Samek Z. The reaction of 1,3-dichloro-l,1,3,3 tetraisopropyldisiloxane with cytosine arabinoside and 1-(6-deoxy-α-l-xylofuranose)uracil. Collection Czechoslov Chern Cornrnun 1980; 45:1860-5.
12. Davson H, Luck CP. Chemistry and rate of turnover of the ocular fluids of the bush baby (Galago crassicaudatus Agisymbanus). J Physiol 1959; 145:433-9. [PMID: 13642310]
13. Jerdan JA, Pepose JS, Michels RG, Hayashi H, de Bustros S, Sebag M, Glaser BM. Proliferative vitreoretinopathy membranes. An immunohistochemical study. Ophthalmology 1989; 96:801-10. [PMID: 2662102]
14. Bringmann A, Pannicke T, Moll V, Milenkovic I, Faude F, Enzmann V, Wolf S, Reichenbach A. Upregulation of P2X(7) receptor currents in Muller glial cells during proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 2001; 42:860-7. [PMID: 11222551]
15. Mojana F, Cheng L, Bartsch DU, Silva GA, Kozak I, Nigam N, Freeman WR. The role of abnormal vitreomacular adhesion in age-related macular degeneration: spectral optical coherence tomography and surgical results. Am J Ophthalmol 2008; 146:218-27. [PMID: 18538742]
16. Li Y, Chen H, Hou J, Zhang Y, Li G, Gu X, Luo L, Shen H, Qu J, Cheng L. Further characterization of ocular safety profile of commercially available preserved and preservative-free triamcinolone acetonide. Retina 2012; 32:364-74. [PMID: 21909054]
17. Soussain C, Suzan F, Hoang-Xuan K, Cassoux N, Levy V, Azar N, Belanger C, Achour E, Ribrag V, Gerber S, Delattre J-Y, Leblond V. Results of Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue in 22 Patients With Refractory or Recurrent Primary CNS Lymphoma or Intraocular Lymphoma. J Clin Oncol 2001; 19:742-9. [PMID: 11157026]
18. Carrabba MG, Reni M, Foppoli M, Chiara A, Franzin A, Politi LS, Villa E, Ciceri F, Ferreri AJ. Treatment approaches for primary CNS lymphomas. Expert Opin Pharmacother 2010; 11:1263-76. [PMID: 20429667]
19. Valluri S, Moorthy RS, Khan A, Rao NA. Combination treatment of intraocular lymphoma. Retina 1995; 15:125-9. [PMID: 7624599]
20. Graham ML, Smiddy WE, Cheo DL, Schachat AP. Intraocular penetration of cytosine arabinoside following subconjunctival administration in primates. J Ocul Pharmacol 1989; 5:255-9. [PMID: 2625619]
21. Assil KK, Hartzer M, Weinreb RN, Nehorayan M, Ward T, Blumenkranz M. Liposome suppression of proliferative vitreoretinopathy. Rabbit model using antimetabolite encapsulated liposomes. Invest Ophthalmol Vis Sci 1991; 32:2891-7. [PMID: 1917392]
22. Al-Aswad LA, Huang M, Netland PA. Inhibition of Tenon's fibroblast proliferation and enhancement of filtration surgery in rabbits with cytosine arabinoside. J Ocul Pharmacol Ther 1999; 15:41-9. [PMID: 10048346]
23. Mietz H, Heimann K. Onset and recurrence of proliferative vitreoretinopathy in various vitreoretinal disease. Br J Ophthalmol 1995; 79:874-7. [PMID: 7488572]
24. Hostetler KY. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Res 2009; 82:A84-98. [PMID: 19425198]
25. Cheng L, Hostetler KY, Lee J, Koh HJ, Beadle JR, Bessho K, Toyoguchi M, Aldern K, Bovet JM, Freeman WR. Characterization of a novel intraocular drug-delivery system using crystalline lipid antiviral prodrugs of ganciclovir and cyclic cidofovir. Invest Ophthalmol Vis Sci 2004; 45:4138-44. [PMID: 15505067]
26. Hou J, Li Y, Zhou Z, Valiaeva N, Beadle JR, Hostetler K, Freeman WR, Hu DN, Chen H, Cheng L. Antiproliferative property of hexadecyloxypropyl 9-[2-(phosphonomethoxy) ethyl] guanine (HDP-PMEG) for unwanted ocular proliferation. Mol Vis 2011; 17:627-37. [PMID: 21386925]
27. Cheng L, Hostetler K, Valiaeva N, Tammewar A, Freeman WR, Beadle J, Bartsch DU, Aldern K, Falkenstein I. Intravitreal crystalline drug delivery for intraocular proliferation diseases. Invest Ophthalmol Vis Sci 2010; 51:474-81. [PMID: 19696179]
28. Aldern KA, Ciesla SL, Winegarden KL, Hostetler KY. Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. Mol Pharmacol 2003; 63:678-81. [PMID: 12606777]
29. Cheng L, Beadle JR, Tammewar A, Hostetler KY, Hoh C, Freeman WR. Intraocular pharmacokinetics of a crystalline lipid prodrug, octadecyloxyethyl-cyclic-cidofovir, for cytomegalovirus retinitis. J Ocul Pharmacol Ther 2011; 27:157-62. [PMID: 21351867]